Research programme: cancer therapeutics - Kancera

Drug Profile

Research programme: cancer therapeutics - Kancera

Alternative Names: HDAC6 inhibitors - Kancera

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Kancera
  • Class Antineoplastics
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Multiple myeloma; Solid tumours

Most Recent Events

  • 09 Sep 2016 Early research in Multiple myeloma in Sweden (Parenteral) before September 2016 (Kancera Pipeline, September 2016)
  • 09 Sep 2016 Early research in Solid tumours in Sweden (Parenteral) before September 2016 (Kancera Pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top